Mutagenesis at Pro309 of single-chain urokinase-type plasminogen activator alters its catalytic properties

Proteins: Structure, Function and Genetics

Volumn 61, Issue 4, 2005, Pages 870-877

  Sun, Ziyong ^a   Liu, Jian Ning ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Amidolytic activity; Cassette mutagenesis; Fibrin fragment D dimer; Fibrin fragment E; Plasminogen activation; Secondary site(s) of substrate interaction; Substrate specificity

Indexed keywords

AMINO ACID; COMPLEMENTARY DNA; D DIMER; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT E; PLASMINOGEN ACTIVATOR; PROLINE; PROUROKINASE; UNCLASSIFIED DRUG; PEPTIDE FRAGMENT; PLASMINOGEN; PRIMER DNA; RECOMBINANT PROTEIN; UROKINASE;

ARTICLE; ENZYME SPECIFICITY; ENZYME SUBSTRATE; GENE EXPRESSION; MUTAGENESIS; NUCLEOTIDE SEQUENCE; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN PURIFICATION; AMINO ACID SUBSTITUTION; BINDING SITE; CATALYSIS; CHEMISTRY; ENZYME ACTIVATION; ENZYME ACTIVE SITE; GENETICS; KINETICS; METABOLISM; MOLECULAR CLONING; PROTEIN SECONDARY STRUCTURE; SITE DIRECTED MUTAGENESIS;

AMINO ACID SUBSTITUTION; BASE SEQUENCE; BINDING SITES; CATALYSIS; CATALYTIC DOMAIN; CLONING, MOLECULAR; DNA PRIMERS; DNA, COMPLEMENTARY; ENZYME ACTIVATION; KINETICS; MUTAGENESIS, SITE-DIRECTED; PEPTIDE FRAGMENTS; PLASMINOGEN; PROLINE; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT PROTEINS; URINARY PLASMINOGEN ACTIVATOR;

EID: 28644441521     PISSN: 08873585     EISSN: None     Source Type: Journal    
DOI: 10.1002/prot.20686     Document Type: Article

References (35)

1. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, Van denOord JJ, Collen D, Mulligan RC. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994;368:419-424.
2. Carmeliet P, Collen D. Targeted gene manipulation and transfer of the plasminogen and coagulation systems in mice. Fibrinolysis 1996;10:195-213.
3. Petersen LC, Lund LR, Dano K, Nielsen LS, Skriver L. One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J Biol Chem 1988;263:11189-11195.
4. Liu J, Gurewich V. The kinetics of plasminogen activation by thrombin-cleaved pro-urokinase and promotion of its activity by fibrin fragment E-2 and by tissue plasminogen activator. Blood 1993;81:980-987.
5. Lijnen HR, Van Hoef B, Nelles L, Collen D. Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740→ Ala) and plasmin-resistant scu-PA (Lys158→ Glu). J Biol Chem 1990;265:5232-5236.
6. Gurewich V, Pannell R, Broeze RJ, and Mao J. Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158). J Clin Invest 1988;82:1956-1962.
7. Tate KM, Higgins DL, Holmes WE, Winkler ME, Heyneker HL, Vehar GA. Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis. Biochemistry 1987;26:338-343.
8. Strandberg L, Medison EL. Variants of tissue-type plasminogen activator with substantially enhanced response and selectivity toward fibrin co-factors. J Biol Chem 1995;270:23444-23449.
9. Petersen LC, Boel E, Johannessen M, Foster D. Quenching of the amidolytic activity of one-chain tissue-type plasminogen activator by mutation of lysine-416. Biochemistry 1990;29:3451-3457.
10. Tachias K, Madison EL. Converting tissue type plasminogen activator into a zymogen. Important role of Lys156. J Biol Chem 1997;272:28-31.
11. Lamba D, Bauer M, Huber R, Fischer S, Rudolph R, Kohnert U, Bode W. The 2.3 A crystal structure of the catalytic domain of recombinant two-chain human tissue-type plasminogen activator. J Mol Biol 1996;258:117-135.
12. Liu J, Tang W, Sun Z, Kung W, Pannell R, Sarmientos P, Gurewich V. A site-directed mutagenesis of pro-urokinase which substantially reduces its intrinsic activity. Biochemistry 1996;35:14070-14076.
13. Madison EL, Kobe A, Gething M, Sambrook JF, Goldsmith EJ. Converting tissue plasminogen activator to a zymogen: a regulatory triad of Asp-His-Ser. Science 1993;262:419-421.
14. Pannell R, Gurewich V. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 1986;67:1215-1223.
15. Rijken DC, Hoylaerts M, Collen D. Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. J Biol Chem 1982;257:2920-2925.
16. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982;257:2912-2919.
17. Ranby M. Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophy Acta 1982;704:461-469.
18. Gurewich V, Pannell R. The fibrin specificity of single chain-urokinase (sc-UK) induced proteolysis is not dependent on fibrin binding. Thromb Haemost 1983;50:386.
19. Angles-Cano E, Pannell R, Gurewich V. Pro-urokinase (Pro-UK), the single-chain urokinase-type plasminogen activator (scu-PA) does not bind to fibrin. Isotopic and spectrophotometric studies using fibrin in solid-phase. Blood 1986;(Suppl 1):343.
20. Liu J, Gurewich V. A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin. J Clin Invest 1991;88:2012-2017.
21. Shotton DM, Watson HC. Three-dimensional structure of tosylelastase. Nature 1970;225:811-816.
22. Stroud RM, Kay LM., Dickerson RE. The structure of bovine trypsin: electron density maps of the inhibited enzyme at 5 Angstrom and at 2-7 Angstron resolution. J Mol Biol 1974;83:185-208.
23. Ke S, Tachias K, Lamba D, Bode W, Madison EL. Identification of a hydrophobic exosite on tissue type plasminogen activator that modulates specificity for plasminogen. J Biol Chem 1997;272:1811-1816.
24. Nienaber V, Wang J, Davidson D, Henkin J. Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite. J Biol Chem 2000;275:7239-7248.
25. Zeslawska E, Schweinitz A, Karcher A, Sondermann P, Sperl S, Sturzebecher J, Jacob U. Crystals of the urokinase type plasminogen activator variant beta(c)-uPAin complex with small molecule inhibitors open the way towards structure-based drug design. J Mol Biol 2000;301:465-475.
26. Zeslawska E, Jacob U, Schweinitz A, Coombs G, Bode W, Madison E. Crystals of urokinase type plasminogen activator complexes reveal the binding mode of peptidomimetic inhibitors. J Mol Biol 2003;328:109-118.
27. Sun Z, Jiang Y, Ma Z, Wu H, Liu B, Xu Y, Tang W, Chen Y, Li C, Zhu D, Gurewich V, Liu J. Identification of a flexible loop region (297-313) of urokinase-type plasminogen activator, which helps determine its catalytic activity. J Biol Chem 1997;272:23818-23823.
28. Ke S, Coombs GS, Tachias K, Corey DR, Madison EL. Optimal subsite occupancy and design of a selective inhibitor of urokinase. J Biol Chem 1997;272:20456-20462.
29. Castellino FJ, Powell JR. Human plasminogen. Methods Enzymol 1981;80:365-378.
30. Sun Z, Liu B, Chen Y, Gurewich V, Zhu D, Liu J. Analysis of the forces which stabilize the active conformation of urokinase-type plasminogen activator. Biochemistry 1998;37:2935-2940.
31. Winkler ME, Blaber M. Purification and characterization of recombinant single-chain urokinase produced in Escherichia coli. Biochemistry 1986;25:4041-4045.
32. Swaim WR, Feders MB. Fibrinogen assay. Clin Chem 1967;13:1026-1028.
33. Ding L, Coombs GS, Strandberg L, Navre M, Corey DR, Madison, EL. Origins of the specificity of tissue-type plasminogen activator. Proc Natl Acad Sci USA 1995;92:7627-7631.
34. Bianchini EP, Pike RN, Le Bonniec BF. The elusive role of the potential factor X cation-binding exosite-1 in substrate and inhibitor interactions. J Biol Chem 2004;279:3671-3679.
35. Chuang Y, Swanson R, Raja SM, Olson ST. Heparin enhances the specificity of antithrombin for thrombin and factor Xa independent of the reactive center loop sequence. Evidence for an exosite determinant of factor Xa specificity in heparin-activated antithrombin. J Biol Chem 2001;276:14961-14971.